Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

26.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57
Open 26.04
Bid (Size) 22.11 (3)
Ask (Size) 27.80 (5)
Prev. Close 26.04
Today's Range 26.04 - 26.04
52wk Range 15.82 - 29.93
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Corcept Therapeutics Return On Capital Employed Overview
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades 
Via Benzinga

Performance

YTD
+28.02%
+28.02%
1 Month
+0.31%
+0.31%
3 Month
+5.25%
+5.25%
6 Month
+7.69%
+7.69%
1 Year
+30.13%
+30.13%

More News

Read More
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
Via Investor's Business Daily
3 Biotech Stocks Outperforming a Bear Market
Via InvestorPlace
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Via Investor's Business Daily
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
Via Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Via Benzinga
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
Via Benzinga
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Why Corcept's Pill — And Stock — Is Getting Renewed Attention After Abortion Ruling
Via Investor's Business Daily
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
Via Investor's Business Daily
Top Mid-Cap Stocks: Trading Opportunities For Next Week - Sunday, June 19
Via Talk Markets
Corcept Update
Via NewMediaWire
NASDAQ:CORT Investor Alert: Investigation over Potential Wrongdoing at Corcept Therapeutics Incorporated
Via SBWire
Preview: Corcept Therapeutics's Earnings
Via Benzinga
Corcept Shareholder Notice
Via NewMediaWire
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shareholder Alert: Update on Lawsuit Against Corcept Therapeutics
Via SBWire
Corcept Therapeutics's Return On Capital Employed Overview
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.